Jun 2026 (Q1 FY27) — Aug 13, 2026
Aethlon Medical Q1 FY27 — Oncology Trial Advances, Cash Position Strengthened
Read the full callAethlon Medical (AEMD) earnings
- Jun 2026
- Jun 2026 (Q1 FY27)
- Mar 2026
Aethlon Medical earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -1.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$5.16 +0.19% · +$0.01
Performance −81.0% 1Y
1Y: $27.15 on 17 Oct 2025 → $5.16. High $28.75 (29 Oct 2025), low $1.43 (16 Sept 2026).
- Previous close
- $5.15
- 52-week range
- $1.43 – $28.75
- One year
- −81.27%
Overview
- Symbol
- AEMD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q4 FY26) — Jun 10, 2026
Aethlon Medical Q4 FY26 — Hemopurifier oncology trial advances to final cohort under tight cost control
Read the full callEvery analysed call
Aethlon Medical earnings calls (AEMD)
Financials
What the filings say
Net profit, year on year: +12% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -3 | -2 | -2 | -2 | -2 | -2 | -2 | -2 |
| Net profit | -3 | -2 | -6 | -2 | -1 | -2 | -2 | -2 |
| EPS ($ per share) | -16.11 | -10.05 | — | -42.42 | -3.74 | -2.45 | — | -4.02 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -106 | -112 | -120 | -130 | -142 | -155 | -168 | -175 |
| Total liabilities | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 1 |
| Fixed assets | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Total assets | 4 | 10 | 11 | 19 | 18 | 8 | 7 | 6 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4 | -5 | -7 | -10 | -11 | -10 | -8 | -7 |
| Cash from investing | 0 | -0 | -0 | -0 | -1 | -0 | 0 | -0 |
| Cash from financing | 1 | 11 | 7 | 17 | 9 | 1 | 8 | 7 |
| Net cash flow | — | — | — | 7 | -3 | -9 | 0 | -0 |
| Capital expenditure | 0 | -0 | -0 | -0 | -1 | -0 | 0 | -0 |
| Free cash flow | -4 | -5 | -7 | -10 | -11 | -10 | -8 | -7 |
Insider filings
18 filings between Dec 31, 2025 and Oct 8, 2026.
Open market
decisions to buy or sellNobody bought or sold AEMD on the open market in this window. The filings below are 6 awards and 12 tax withholdings.
Compensation
not trading decisions- 6
- Award — granted as compensation
- 12
- Tax withheld — shares kept back by the company to cover tax
Latest filings (37)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2026 | LAROSA STEVEN P Chief Medical Officer | Award | 42,000 | $0 |
| Oct 8, 2026 | FRAKES JAMES B CFO/CEO | Award | 42,000 | $0 |
| Sep 30, 2026 | Gikakis Nicolas Director | Tax withheld | 436 | $2.8K |
| Sep 30, 2026 | Shah Chetan Director | Tax withheld | 436 | $2.8K |
| Sep 30, 2026 | BROENNIMAN EDWARD G Director | Tax withheld | 218 | $1.4K |
| Jun 30, 2026 | Gikakis Nicolas Director | Tax withheld | 2,182 | $1.8K |
| Jun 30, 2026 | BROENNIMAN EDWARD G Director | Tax withheld | 1,091 | $895 |
| Jun 30, 2026 | Shah Chetan Director | Tax withheld | 2,182 | $1.8K |
| Apr 17, 2026 | Rossetti Angela Director | Award | 21,815 | $50.0K |
| Apr 17, 2026 | BROENNIMAN EDWARD G Director | Award | 21,815 | $50.0K |
| Apr 17, 2026 | Gikakis Nicolas Director | Award | 21,815 | $50.0K |
| Apr 17, 2026 | Shah Chetan Director | Award | 21,815 | $50.0K |
| Mar 31, 2026 | BROENNIMAN EDWARD G Director | Tax withheld | 89 | $195 |
| Mar 31, 2026 | Gikakis Nicolas Director | Tax withheld | 178 | $390 |
| Mar 31, 2026 | Shah Chetan Director | Tax withheld | 178 | $390 |
| Dec 31, 2025 | BROENNIMAN EDWARD G Director | Tax withheld | 89 | $247 |
| Dec 31, 2025 | Gikakis Nicolas Director | Tax withheld | 179 | $496 |
| Dec 31, 2025 | Shah Chetan Director | Tax withheld | 179 | $496 |
| Sep 30, 2025 | Shah Chetan Director | Tax withheld | 1,786 | $1.3K |
| Sep 30, 2025 | Gikakis Nicolas Director | Tax withheld | 1,786 | $1.3K |
| Sep 30, 2025 | BROENNIMAN EDWARD G Director | Tax withheld | 893 | $669 |
| Jun 30, 2025 | Shah Chetan Director | Tax withheld | 1,786 | $2.1K |
| Jun 30, 2025 | Gikakis Nicolas Director | Tax withheld | 1,786 | $2.1K |
| Jun 30, 2025 | BROENNIMAN EDWARD G Director | Tax withheld | 893 | $1.1K |
| Apr 23, 2025 | Shah Chetan Director | Award | 142,857 | $51.1K |
| Apr 23, 2025 | BROENNIMAN EDWARD G Director | Award | 142,857 | $50.0K |
| Apr 23, 2025 | Rossetti Angela Director | Award | 142,857 | $50.0K |
| Apr 23, 2025 | Gikakis Nicolas Director | Award | 142,857 | $50.0K |
| Mar 31, 2025 | Gikakis Nicolas Director | Tax withheld | 3,289 | $1.2K |
| Mar 31, 2025 | BROENNIMAN EDWARD G Director | Tax withheld | 1,645 | $589 |
| Mar 31, 2025 | Shah Chetan Director | Tax withheld | 3,289 | $1.2K |
| Dec 31, 2024 | Shah Chetan Director | Tax withheld | 3,289 | $2.8K |
| Dec 31, 2024 | BROENNIMAN EDWARD G Director | Tax withheld | 1,645 | $1.4K |
| Dec 31, 2024 | Gikakis Nicolas Director | Tax withheld | 3,289 | $2.8K |
| Sep 30, 2024 | Shah Chetan Director | Tax withheld | 3,289 | $1.5K |
| Sep 30, 2024 | Gikakis Nicolas Director | Tax withheld | 3,289 | $1.5K |
| Sep 30, 2024 | BROENNIMAN EDWARD G Director | Tax withheld | 1,645 | $767 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AETHLON MEDICAL INC
Free account. Everything above stays public.
Write why you follow AETHLON MEDICAL INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading